Claudia Agudelo

Claudia Agudelo

Auto-generated profile, based on publicly available information

Claudia Agudelo

Center of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
CPCarolina Pavlovsky
Carolina Pavlovsky
VPVirginia Abello Polo
Virginia Abello Polo
KPKatia Pagnano
Katia Pagnano
AVAna Ines Varela
Ana Ines Varela
CAClaudia Agudelo
Claudia Agudelo
JCJorge Cortes
Jorge Cortes
Tyrosine kinase inhibitors (TKIs) have dramatically changed the survival of chronic myeloid leukemia (CML) patients, and treatment-free remission (TFR) has recently emerged as a new goal of CML treatment. The aim of this work was to develop recommendations for TKI discontinuation in Latin America (LA), outside of clinical trials. A working group of CML experts from LA discussed 22 questions regarding TFR and reached a consensus for TFR recommendations in the region. TFR is indicated in patients in first chronic phase, with typical BCR-ABL transcripts, under TKI treatment of a minimum of 5 years, in sustained deep molecular response (DMR; molecular response 4.5 [MR4.5]) for 2 years. Sustained DMR must be demonstrated on at least 4 international reporting scale quantitative polymerase chain reaction (PCR) tests, separated by at least 3 months, in the immediate prior 2 years. After second-line therapy, TFR is indicated in previously intolerant, not resistant, patients. Molecular monitoring is recommended monthly for the first 6 months, every 2 to 3 months from months 7 to 12, and every 3 months during the second year, indefinitely. Treatment should be reintroduced if major molecular response is lost. Monitoring of withdrawal syndrome, glucose levels, and lipid profile is recommended after discontinuation. After TKI reintroduction, molecular monitoring is indicated every 2 to 3 months until MR4.0 achievement; later, every 3 to 6 months. For the TFR attempt, having standardized and reliable BCR-ABL PCR tests is mandatory. These recommendations will be useful for safe discontinuation in daily practice and will benefit patients who wish to stop treatment in emergent regions, in particular, with TKI-related chronic adverse events.

24 October 2023 in Journal of Cancer Education
Verified
Journal Article
Closed access
PDF file
JGJuan Guio
Juan Guio
AMAndrés Melo
Andrés Melo
MSMateo Mejía Saldarriaga
Mateo Mejía Saldarriaga
CFCynthia Fuentes
Cynthia Fuentes
NTNatalia Tíjaro-Ovalle
Natalia Tíjaro-Ovalle
MRMartha Romero
Martha Romero